The King of Ozempic Is Scared as Hell
Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?
Read More
Novo Nordisk reports positive next-generation obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday.
Read MoreEnd of content
No more pages to load